153 related articles for article (PubMed ID: 36760745)
21. Design, synthesis, and biological evaluation of a potent PLK4 inhibitor WY29 with 1H-pyrazolo[3,4-d]pyrimidine scaffold.
Wang L; Sun Y; Wang J; Xue Y; Sun Y; Qin Q; Sun Y; Zhao D; Cheng M
Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200490. PubMed ID: 36442843
[TBL] [Abstract][Full Text] [Related]
22. Identification of 1
Sun Y; Tang H; Wang X; Feng F; Fan T; Zhao D; Xiong B; Xie H; Liu T
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1411-1425. PubMed ID: 35587686
[TBL] [Abstract][Full Text] [Related]
23. Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor.
Ito T; Kinoshita K; Tomizawa M; Shinohara S; Nishii H; Matsushita M; Hattori K; Kohchi Y; Kohchi M; Hayase T; Watanabe F; Hasegawa K; Tanaka H; Kuramoto S; Takanashi K; Oikawa N
J Med Chem; 2022 Sep; 65(18):12427-12444. PubMed ID: 36066182
[TBL] [Abstract][Full Text] [Related]
24. 3-Aminopyrazolo[3,4-b]pyridine: Effective Precursor for Barium Hydroxide-Mediated Three Components Synthesis of New Mono- and Bis(pyrimidines) with Potential Cytotoxic Activity.
Sanad SMH; Mekky AEM
Chem Biodivers; 2022 Jan; 19(1):e202100500. PubMed ID: 34784450
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of 6-(pyrimidin-4-yl)-1H-pyrazolo[4,3-b]pyridine derivatives as novel dual FLT3/CDK4 inhibitors.
Li X; Yang T; Hu M; Yang Y; Tang M; Deng D; Liu K; Fu S; Tan Y; Wang H; Chen Y; Zhang C; Guo Y; Peng B; Si W; Yang Z; Chen L
Bioorg Chem; 2022 Apr; 121():105669. PubMed ID: 35180490
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrrolo[2,3-b]pyridine derivatives as potential anti-tumor agents.
Wang R; Chen Y; Yang B; Yu S; Zhao X; Zhang C; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Jan; 94():103474. PubMed ID: 31859010
[TBL] [Abstract][Full Text] [Related]
27. Hydrazide-hydrazones as Small Molecule Tropomyosin Receptor Kina se A (TRKA) Inhibitors: Synthesis, Anticancer Activities,
Alam MS; Lee DU
Med Chem; 2022; 19(1):47-63. PubMed ID: 35490310
[TBL] [Abstract][Full Text] [Related]
28. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.
Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA
Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review.
El-Nassan HB; Al-Qadhi MA
Eur J Med Chem; 2023 Oct; 258():115618. PubMed ID: 37413881
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAF
Wang Y; Wan S; Li Z; Fu Y; Wang G; Zhang J; Wu X
Eur J Med Chem; 2018 Jul; 155():210-228. PubMed ID: 29886324
[TBL] [Abstract][Full Text] [Related]
31. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors.
Cui S; Wang Y; Wang Y; Tang X; Ren X; Zhang L; Xu Y; Zhang Z; Zhang ZM; Lu X; Ding K
Eur J Med Chem; 2019 Oct; 179():470-482. PubMed ID: 31271959
[TBL] [Abstract][Full Text] [Related]
33. Discovery of novel phenyl triazole analogs as TRK/ALK dual inhibitors with prospective antitumor effects.
Cao Z; Zhang J; Guo M; Shao B; Wei X; Li S; Wang P; Zhai X
Bioorg Chem; 2023 Jul; 136():106563. PubMed ID: 37121107
[TBL] [Abstract][Full Text] [Related]
34. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L
Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of novel 1H-Pyrazolo[3,4-b]pyridine derivatives as DYRK 1A/1B inhibitors.
Park A; Hwang J; Lee JY; Heo EJ; Na YJ; Kang S; Jeong KS; Kim KY; Shin SJ; Lee H
Bioorg Med Chem Lett; 2021 Sep; 47():128226. PubMed ID: 34182093
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and bioevaluation of N-(3,4,5-trimethoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-3-amines as tubulin polymerization inhibitors with anti-angiogenic effects.
Hao SY; Qi ZY; Wang S; Wang XR; Chen SW
Bioorg Med Chem; 2021 Feb; 31():115985. PubMed ID: 33421913
[TBL] [Abstract][Full Text] [Related]
38. Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy.
Xiang S; Wang J; Huang H; Wang Z; Song X; Zhou Y; Jin F; He X; Zhang ZM; Tu Z; Ding K; Zhang Z; Lu X
Eur J Med Chem; 2023 Jan; 245(Pt 1):114899. PubMed ID: 36410169
[TBL] [Abstract][Full Text] [Related]
39. Syntheses and evaluation of carbon-11- and fluorine-18-radiolabeled pan-tropomyosin receptor kinase (Trk) inhibitors: exploration of the 4-aza-2-oxindole scaffold as Trk PET imaging agents.
Bernard-Gauthier V; Aliaga A; Aliaga A; Boudjemeline M; Hopewell R; Kostikov A; Rosa-Neto P; Thiel A; Schirrmacher R
ACS Chem Neurosci; 2015 Feb; 6(2):260-76. PubMed ID: 25350780
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and biological activity of bicyclic carboxamide derivatives as TRK inhibitors.
Sun M; Cai S; Li P; Zhang F; Zhang H; Zhou J
Bioorg Med Chem; 2020 Dec; 28(23):115811. PubMed ID: 33069129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]